Literature DB >> 8868446

Characterization of lethal factor binding and cell receptor binding domains of protective antigen of Bacillus anthracis using monoclonal antibodies.

Stephen F Little1, Jeanne M Novak1, John R Lowe1, Stephen H Leppla1, Yogendra Singh2, Kurt R Klimpel2, Burton C Lidgerding1, Arthur M Friedlander1.   

Abstract

Lethal toxin from Bacillus anthracis is composed of protective antigen (PA) and lethal factor (LF). Anti-PA mAbs that neutralized lethal toxin activity, either in vivo or in vitro, identified three non-overlapping antigenic regions on PA. Two distinct antigenic regions were recognized by the four mAbs that neutralized lethal toxin activity by inhibiting the binding of 125I-LF to cell-bound PA. Mapping showed that one mAb, 1G3PA63, recognized an epitope on a 17 kDa fragment located between amino acid residues Ser-168 and Phe-314. The three other mAbs, 2D3PA, 2D5PA and 10D2PA, recognized an epitope between amino acids Ile-581 and Asn-601. A single antigenic region was recognized by the three mAbs, 3B6PA, 14B7PA and 10E10PA63, that inhibited binding of 125I-PA to cells. This region was located between amino acids Asp-671 and Ile-721. These results confirm previously defined functional domains of PA and suggest that LF may interact with two different sites on PA to form lethal toxin.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8868446     DOI: 10.1099/13500872-142-3-707

Source DB:  PubMed          Journal:  Microbiology (Reading)        ISSN: 1350-0872            Impact factor:   2.777


  51 in total

1.  Clostridium perfringens iota-toxin: mapping of receptor binding and Ia docking domains on Ib.

Authors:  J C Marvaud; T Smith; M L Hale; M R Popoff; L A Smith; B G Stiles
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

2.  Involvement of domain 3 in oligomerization by the protective antigen moiety of anthrax toxin.

Authors:  J Mogridge; M Mourez; R J Collier
Journal:  J Bacteriol       Date:  2001-03       Impact factor: 3.490

3.  Identification of amino acid residues of anthrax protective antigen involved in binding with lethal factor.

Authors:  Vibha Chauhan; Rakesh Bhatnagar
Journal:  Infect Immun       Date:  2002-08       Impact factor: 3.441

Review 4.  Development of an improved vaccine for anthrax.

Authors:  Stephen H Leppla; John B Robbins; Rachel Schneerson; Joseph Shiloach
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

5.  Analysis of antibody responses to protective antigen-based anthrax vaccines through use of competitive assays.

Authors:  Rebecca A Brady; Anita Verma; Bruce D Meade; Drusilla L Burns
Journal:  Clin Vaccine Immunol       Date:  2010-07-14

6.  Receptor-specific requirements for anthrax toxin delivery into cells.

Authors:  G Jonah A Rainey; Darran J Wigelsworth; Patricia L Ryan; Heather M Scobie; R John Collier; John A T Young
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-01       Impact factor: 11.205

7.  Characterization of a permissive epitope insertion site in adenovirus hexon.

Authors:  Michael J McConnell; Xavier Danthinne; Michael J Imperiale
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

8.  Selection and evaluation of the immunogenicity of protective antigen mutants as anthrax vaccine candidates.

Authors:  Ming Yan; Michael H Roehrl; Emre Basar; Julia Y Wang
Journal:  Vaccine       Date:  2007-12-26       Impact factor: 3.641

9.  Efficacy of ETI-204 monoclonal antibody as an adjunct therapy in a New Zealand white rabbit partial survival model for inhalational anthrax.

Authors:  Bethany Biron; Katie Beck; David Dyer; Marc Mattix; Nancy Twenhafel; Aysegul Nalca
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

10.  Domain specificity of the human antibody response to Bacillus anthracis protective antigen.

Authors:  Donald C Reason; Anuska Ullal; Justine Liberato; Jinying Sun; Wendy Keitel; Jianhui Zhou
Journal:  Vaccine       Date:  2008-06-02       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.